ACE2 and COVID-19: The RBD‐specific antibodies induced in the PreS‐RBD‐immunized subject were found to block more strongly the binding of RBD to ACE2 than those obtained from subjects after full vaccination with currently available and licensed COVID‐19 vaccines and from COVID‐19 convalescent patients when determined by their median blocking activity (Table 1).